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CHARACTERIZATION OF FC RECEPTOR FAMILY PROTEINS IN VAGINAL 
AND ENDOCERVICAL EPITHELIA 
SUPREETHA GUBBALA  
 
ABSTRACT 
In the age of highly active antiretroviral therapy (HAART), patients infected with 
Human Immunodeficiency Virus Type 1 (HIV-1) are now living significantly healthier 
and longer lives. However, HIV prevention and cure still remain significant challenges. 
Globally, women face specific barriers to using and accessing both female and male 
condoms, the primary method recommended by the World Health Organization (WHO) 
to prevent sexual transmission of HIV-1.  Although HAART treatment as prevention 
(TasP) of HIV has shown promising preliminary results, poor economic feasibility of the 
method in resource poor settings has yet to be resolved. Since women carry over 50% of 
the disease burden, there is a significant need for the development of a female-controlled 
method of prevention. One such approach is the reformulation of topical vaginal 
microbicides. Our laboratory is developing HIV-targeted microbicide formulations that 
utilize highly specific, broadly neutralizing anti-HIV antibodies (bNAbs). 
The purpose of my research project was to characterize Fc receptor expression in 
epithelial cell models of the lower female genital tract with a particular focus on the 
neonatal Fc receptor (FcRn).  Fc receptors are a large family of proteins that bind to the 
Fc region of immunoglobulins (Igs) and function in Ig transport and effector functions. 
These receptors could function in enhancing the delivery of bNAbs in microbicide 
	  	   vii 
formulations or potentially serve as a mechanism of delivering HIV to target cells in 
tissues via transport of HIV-antibody complexes.  Thus, this thesis assesses Fc receptor 
expression in human vaginal and endocervical organotypic cultures via microarray, 
quantitative RT-PCR, immunohistology and preliminary functional assays.  
Microarray results revealed significant expression of Fc receptor family genes in 
the epithelial cells of the lower female reproductive tract (FRT).  The polymeric 
immunoglobulin receptor (pIgR), a well-characterized receptor that transports secretory 
IgA across mucosal epithelia, was abundantly expressed and hormonally regulated in 
epithelial cells of the vagina and endocervix. FcRn, a receptor originally characterized in 
the placenta and gut where it confers passive immunity from mother-to-child via 
bidirectional IgG transcytosis, was expressed in both tissue models.  Moreover, several 
members of the novel FC receptor-like (FCRL) family were detected by microarray in 
both models. 
Immunohistological staining revealed pIgR protein in the endocervical mucosal 
epithelium, confirming current literature describing its expression in the FRT and role in 
local production of cervicovaginal secretions. FcRn protein expression was detected in 
the basal cell layer of the stratified squamous vaginal epithelium and in the columnar 
cells of the endocervix. Preliminary functional assays did not observe FcRn-specific 
transcytosis of human IgG across vaginal or endocervical epithelia by ELISA or 
immunohistology. VRCO1, a monoclonal antibody in development for application in 
microbicide formulation, crossed the epithelium, but was likely not transcytosed via 
FcRn because immunohistology revealed the presence of antibody between epithelial 
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cells rather than the expected intracellular localization of IgG utilized in the FcRn 
mechanism. 
These preliminary findings indicate that Fc receptors, pIgR and Fc receptor-like 
proteins may play an important role in antibody-mediated immune responses in the FRT. 
Further research is require to determine whether FcRn functions in HIV-antibody 
complex-mediated HIV transmission or monoclonal antibody transcytosis. 	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INTRODUCTION 
It has been over three decades since the Human Immunodeficiency Virus Type 1 
(HIV-1) was first isolated in the laboratories of Robert Gallo and Luc Montagnier (Gallo 
et al., 1983)(Barré-Sinoussi et al., 1983). Within the decade after its recognition in the 
U.S., the mysterious disease caused by HIV-1, called Acquired Immune Deficiency 
Syndrome (AIDS), began to be documented globally and soon became one of the most 
avidly researched diseases in the world. In the early stages of the epidemic a significant 
number of cases were acquired through transfused blood products.  Now HIV-1 is 
primarily transmitted by sexual intercourse, intravenous drug users and maternal-to-fetal 
transmission.  In 2000, the United Nations declared the combat of HIV/AIDS as number 
6 in its list of Millennium Development Goals (MDGs), aiming to have halted and 
reversed the spread of the disease by 2015 and provide universal treatment access by 
2010 (UNAIDS, 2013). 
Now with the advent of HAART, many individuals living with the disease have 
greater access to and choice in treatment. Yet in the arena of prevention of HIV 
transmission by sexual intercourse, condoms remain the primary World Health 
Organization (WHO) recommended method worldwide. In addition to condom use, the 
WHO also emphasizes male circumcision as an important component of comprehensive 
HIV prevention packages because three large clinical trials revealed a 60% risk reduction 
of heterosexual HIV acquisition in circumcised men (WHO 2014). Although, treatment 
as prevention has recently premiered as an effective prophylactic regimen for HIV 
prevention in serodiscordant couples and high risk populations, the economic feasibility 
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of providing this regimen at low cost to those who need it remains unlikely 
(Bärnighausen, Salomon, & Sangrujee, 2012).  In the U.S. alone, the CDC estimates 
41,400 new infections occur annually with over 900,000 people currently living with the 
disease (Center for Disease Control, 2013). Globally, an estimated 2,500,000 new 
infections were documented in 2012 (UNAIDS, 2013). Since there is no cure for HIV and 
it requires lifelong treatment, the financial cost of the disease surpasses those of other 
STIs and therefore, the need for novel prevention methods has increasingly become the 
focus of research.  
Women make up over 50% of the HIV-1 infected population globally, and face 
unique barriers to accessing treatment and prevention methods (UNAIDS, 2013). With a 
female-controlled prevention method, it is possible to address many of the socioeconomic 
and cultural barriers that prevent condom use. One particular approach has been the 
development of topical vaginal microbicide gels. However, clinical efficacy trials of 
microbicides have shown variable results with most showing no effect and early studies 
of nonoxynol-9 spermicide showing possible transmission enhancing side effects (Garg, 
Nuttall, & Romano, 2009)(Fichorova, Tucker, & Anderson, 2001).  New microbicides  
based on antiretroviral drugs such as Truvada have recently been tested in clinical trials 
with mixed results (Kenney et al., 2011)(van der Straten et al., 2014). Another approach 
is the use of microbicides containing anti-HIV broadly neutralizing antibodies (bNAbs) 
that specifically and effectively inactivate HIV before it can infect a new host. Since 
human antibodies are a natural response to infection, bNAbs may not produce the 
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harmful side effects seen in past microbicide compounds and could work efficiently to 
prevent HIV entry into tissue.  
HIV Virology 
Two variants of HIV have been classified, HIV-1 and HIV-2. HIV-1 is a 
derivative of human infection with the chimpanzee SIVcpz virus and is the major cause 
of the worldwide AIDS epidemic. It is important to note that within HIV-1 there are three 
subgroups and at least ten clades. The three sub-groups are M (Major), N (New) and O 
(Outlier), and within the M category there exist ten clades subtyped from A through J. 
These clades are classified based upon the variation in env and gag gene sequences, can 
exist in recombination of multiple clades and have different transmission characteristics. 
Type B is the most prevalent clade in North America and is found primarily in 
homosexual and intravenous drug user populations (Hunt, 2010).  
HIV belongs to the subclass of lentiviruses under the family of human 
retroviruses. These two classifications characterize the virus by its long incubation period 
and its reverse transcription replication.  The basic structure of a mature HIV virion 
shown in Figure 1 below is a spherical, enveloped nucleocapsid that contains the essential 
components of viral RNA, protease, reverse transcriptase, integrase and several proteins 
essential to infectivity and virus release (Sierra, Kupfer, & Kaiser, 2005). Due to its use 
of reverse transcriptase to replicate in the host cytoplasm, it falls under the retrovirus 
family. The lipid bilayer membrane that coats the nucleocapsid contains about 72 spikes 
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of envelope glycoproteins such as gp120 and gp41 that are integral to association with 
target cells.  
 
Figure 1. HIV Viral Structure. The basic viral structure containing essential gp120 and 
gp41 envelope proteins and enzymes reverse transcriptase and integrase (NIAID, 2009). 
 
The invasion of host cells by HIV, as shown in Figure 2 below, begins with high-
affinity binding between the gp120 viral envelope protein and its target cell receptor, 
CD4.  This particular receptor is found primarily on the surface of helper T cells, 
macrophages and dendritic cells. Once gp120 has bound to CD4, the protein undergoes a 
conformational change allowing binding of the viral envelope to co-receptors, CCR5 or 
CXCR4 (Kasper & Fauci, 2010). A second transmembrane envelope protein, gp41, then 
functions to penetrate the host cell membrane and facilitate the fusion of the HIV virion 
	   5	  
with the target cell. The pre-integration complex, consisting of two single strands of viral 
RNA and enzymes inside a protein capsid, then enters the cytoplasm. While the capsid 
makes its way to the nuclear membrane, the reverse transcriptase transcribes the viral 
RNA into DNA, and the capsid opens to release the newly made DNA. It is at this stage 
that HIV DNA and RNA are vulnerable to degradation by cellular enzymes (Kasper & 
Fauci, 2010). HIV provirus enters the nuclear membrane via pores and integrates into 
host cell chromosomes via integrase.  
This integrated DNA can reside latently within the introns of active genes or be 
expressed to produce active infection. If the cell is activated, HIV mRNA is translated 
into proteins that are packaged with enzymes and genomic RNA at the cells plasma 
membrane. Finally the completed package buds through lipid rafts of the host cell 
membrane where it picks up its elusive lipid bilayer camouflage. The complete HIV life 
cycle is visualized in Figure 2 below. 
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Figure 2. Life Cycle of HIV. Process of viral infection from free virus stage to 
replication within cytoplasm, integration in the nucleus and finally budding of the mature 
virus from the host plasma membrane (Rambaut, Posada, Crandall, & Holmes, 2004). 
 
HIV-1 Transmission 
Since HIV is an enveloped nucleocapsid it generally requires an aqueous environment 
to be transmitted. Clinically, the main routes of HIV transmission have been homosexual 
and heterosexual intercourse, blood transfer, intravenous drug use (IDU) and maternal-to-
fetal vertical transmission via birthing or breastfeeding. In the United States, the CDC 
reported that amongst the estimated 47,500 new HIV infections in 2010, 63% were 
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attributed to men who have sex with men (MSM), 25% to heterosexual intercourse, 8% to 
IDU and 3% to MSM-IDU (CDC 2012). 
Since this thesis will be examining the vaginal and endocervical epithelium, the 
primary analysis will pertain to how the results relate to sexual transmission of HIV. 
Sexual transmission occurs mostly through anal and vaginal sex, and rarely through oral 
sex when seminal fluid is exchanged. Vaginal sex without condom use is classified as a 
high-risk behavior for HIV infection since virus can be found in semen, penile urethral 
secretions, or vaginal secretions. Moreover, HIV has been found to be transmitted more 
easily from men to women than from women to men (“HIV Transmission Basics,” 2014).  
This has been attributed to the ability of HIV to be directly absorbed through the mucosal 
membranes of the vagina and endocervix or enter directly into tissue through an abrasion 
or break in the mucosal epithelium during intercourse. The vaginal mucosa and the 
ectocervix are protected by stratified squamous epithelia which offers better mechanical 
protection against pathogen invasion than the single columnar epithelium of the 
endocervix. However, the average surface area of the vaginal and ectocervical wall is 15 
times larger than that of the endocervix which questions whether or not it provides the 
virus more opportunities to be exposed to breaches in the epithelial barrier (Hladik & 
Hope, 2009) 
Cell-Associated Vs. Cell Free Transmission 
Sexual transmission of HIV-1 can occur by both free virus as well as cell-
associated viruses. Both female macaque infection studies with simian immunodeficiency 
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virus (SIV) and human cervical explant challenges with HIV-1 have confirmed 
transmission via cell-free and cell-associated virus.  Traditionally, HIV prevention 
strategies have focused on cell-free virus, however, increasingly cell-cell transmission 
has been proven to be the more efficient form of transmission and is now being 
considered an important mode of transmission (Anderson et al., 2010)(Abela et al., 2012).   
Recently, it has been shown in rhesus macaques that in mucosal environments 
such as the vaginal, endocervical and anal epithelium cell-cell transmission can be more 
efficient at transmitting virus than cell-free transmission (Kolodkin-Gal et al., 2013).  
This new information particularly impacts HIV vaccine development with neutralizing 
antibodies since they work mainly by blocking gp120 and gp41 epitopes on the viral 
envelope, therefore preventing fusion with host cells. Although, this method has been 
proven to prevent cell-free transmission, the prevention of cell-cell transmission by HIV 
antibodies has been varied and dependent on the antibody and cell type.  
This is particularly relevant in the female reproductive tract (FRT) where 
inefficient anti-HIV IgG coated with HIV-1 can be transcytosed bidirectionally through 
epithelial cells using the neonatal Fc receptor(Gupta et al., 2013) and therefore infect 
immune cells residing deeper in the tissue. This thesis serves to explore this mechanism 
by examining the expression of this particular receptor in epithelial models of both the 
vagina and the endocervix.  
 Disease stage has also been shown to play a significant role in HIV-1 
transmission rates since it is dependent on both plasma virus levels and virus specific 
properties. In addition to a decreased likelihood of treatment and counseling, recently 
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infected individuals in the acute infection stage often have a high level of viral replication 
which makes them potentially more infectious compared to individuals at other stages of 
the disease (Sagar, 2010). However, the estimated infectivity per possible transmission 
event during this stage of the infection is significantly higher than would be predicted 
solely from high plasma viral loads. This finding has raised the question of whether 
particular characteristics of HIV virions produced early in infection could attribute to 
their role as founder viruses in successful HIV transmission. Although, various 
mechanisms of virus selection are thought to contribute to infection by founder viruses, 
the population has to be further studied to establish which particular characteristics 
contribute to enhanced viral infectivity(Sagar, 2010).  
 
 
Figure 3. Mechanisms of HIV Transmission. Transmission can potentially take 
place in the FRT via (a) direct infection of epithelial cells, (b) transcytosis through or (c) 
transmigration past epithelial cells and finally via sampling by Langerhans cells 
(Balzarini & Damme, 2005). 
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Mucosal Immunology of the Female Reproductive Tract 
 Mucosal immune barriers are a vital part of the female reproductive tract and 
serve as the first line of defense against invading pathogens. The two arms of the mucosal 
immune system, the innate and adaptive immune responses, must maintain a delicate 
balance between defending against pathogens and securing an environment conducive to 
embryo growth (Wira, Fahey, Sentman, Pioli, & Shen, 2005). The adaptive arm, which is 
mediated by lymphocytes and antibodies, often takes several days to provide adequate 
protection since the pathogen must first be internalized and presented by antigen-
presenting cells (APCs) that activate T-cells and then proceed to trigger antigen-specific 
antibody production and cytokine cascades.   
The innate immune response involves the APCs, macrophages and dendritic cells, 
(DCs) as well as neutrophils, natural killer cells (NK cells) and epithelial cells.  APCs 
have pattern recognition receptors (PRRs), such as TLRs, on their surface that recognize 
structures of microbes or infected cells that are foreign to the host called pathogen-
associated molecular patterns (PAMPs). More importantly, it has been shown that 
different sections of the FRT carry varying types and levels of innate immune cells. Data 
have indicated that the cervix carries a higher number of CD8+ T cells and APCs in 
comparison to the normal vaginal mucosa, providing further support for its role as a 
primary HIV-1 infection site (Pudney, Quayle, & Anderson, 2005) 
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 Careful regulation of this local immune system is necessary to prepare the FRT 
for the wide range of immune functions it must serve.  The hormones produced during 
the female menstrual cycle provide a way to regulate the FRT environment and its 
immune response status by providing endocrine influence on epithelial cells. Epithelial 
cells of the FRT serve as sentinel cells for pathogen detection as well as physical barriers 
against infection. Both estradiol and progesterone influence cell proliferation, death, 
secretions, receptor expression and cytokine activation within the epithelial layer (Wira et 
al., 2005). Estradiol causes cell proliferation and upregulates progesterone receptors in 
the uterine lining making the epithelial cells permissive to progesterone effects (Cooke et 
al., 1997). More importantly, it has been shown that cultured human endometrial cells 
respond to estrogen by increasing expression of polyimmunoglobulin receptor (pIgR), 
which explains why secretory IgA (sIgA) levels in the lumen are highest during the 
secretory phase (Wira et al., 2005).  sIgA is also transported across the  endocervical 
epithelium, but not the vaginal epithelium (Wira et al., 2005).  
 Recent investigations have also studied effects of synthetic hormones, particularly 
those used in oral contraceptives, on the FRT innate immune environment. Studies have 
shown suppression of IgA and IgG in cervical secretions during the use of oral 
contraceptives, but these results have yet to be confirmed by further study in tissue 
models (Ochiel, Fahey, Ghosh, Haddad, & Wira, 2008). 
 It is currently unknown whether the expression of other Fc receptors involved in 
antibody transport and innate immunity functions in the FRT are affected by endogenous 
or exogenous reproductive hormones.  
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Immunoglobulins 
Immunoglobulins are complex glycoproteins that function as antibodies in the 
adaptive immune response. They are produced by plasma cells to specifically bind a 
foreign antigen that has been recognized by B cells. Antibody binding can result in 
activation of the complement system, which can kill invading pathogens in two ways:  
activated complement can directly lyse its target, or mark it for other immune cells to 
terminate via the opsonization process (Mayer, 2009).  
All antibodies are Y-shaped proteins made up of two light chains and two heavy 
chains bound together by inter-chain and intra-chain disulfide bonds. The chains are 
divided into to two main regions based on sequence variability, accordingly named the 
variable (V) regions and the constant (C) regions. The particular part of antibody 
structure that allows for the great diversity in antigen specificity is called the 
hypervariable region and it is located on the tip of the immunoglobulin protein in the Fab 
region. The Fc region is the tail of the antibody that interacts with Fc receptors on the 
surface of cells and complement. 
Immunoglobulins are classified into five main classes based the structure of their 
heavy chains: IgG, IgM, IgA, IgD and IgE. Within these classes, there is further 
subdivision based upon light chain variability and small differences within the constant 
regions. Each class of molecules has a particular structure and general function, which 
has been summarized in the table below.  
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Table 1. Major Immunoglobulin Classes. Each class of antibodies has a distinct 
function and structure which determines low-affinity or high-affinity binding to their 
targets (“Antibodies,” 2013).  
This thesis focuses on IgGs because this Ig subclass has been found to be 
bidirectionally transcytosed by the FcRn receptor in the intestinal epithelium in 
vivo(Dickinson et al., 1999). If infectious virus is incorporated into IgG-immune 
complexes and is not efficiently neutralized, it may be transported into tissue where it can 
infect susceptible CD4+ target cells (Gupta et al. 2013). This can serve as a potential HIV 
transmission mechanism and should be considered in formulation of vaccine and 
monoclonal antibody-based microbicide strategies.  
Fc Receptor Family  
Receptors for the Fc domain of immunoglobulins are found on the surface of a 
wide range of cells.  These proteins specifically bind to the Fc region of the antibody, 
often after it attaches to a particular pathogen or infected cell marked for termination.   
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Fc receptors have been divided into classes based upon the type of 
immunoglobulin they bind to and further divided by their particular affinities to the 
immunoglobulin. Microarray analyses included in this thesis examined expression of Fc 
family receptors in vaginal and endocervical epithelial cells.  We also studied the 
expression of pIgR, which is technically not an Fc receptor, but binds to sIgA via its 
attachment to the secretory component.   A summary table of the various members of the 
Fc receptor family, their binding specificities and their immune functions has been 
included below. 
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Table 2. Fc Receptor Family. Fc receptors vary by affinity for a particular 
immunoglobulin as well as cellular distribution in the body. This contributes to their 
major role in antibody dependent cellular toxicity (ADCC) and their diverse range of 
coverage. 
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Over the past decade, a novel group of immunoglobulin orphan receptors called 
the Fc receptor-like (FCRL) proteins have been classified. The name of this group is 
derived from the many commonalities this group of proteins shares with the traditional Fc 
receptors for IgG and IgE. Both gene families are located on chromosome 1q21-23, and 
FCRLs contain extracellular sequence similarities and immunoglobulin domains that 
resemble the Fc-binding domain of FcRs (Ehrhardt et al., 2007). Currently, six type 1 
transmembrane receptors (FCRL1-6) and two intracellular proteins (FCRLA and B)  have 
been classified (Davis, 2007). Although it is known that the transmembrane receptors 
contain immunoreceptor tyrosine-based inhibition motifs (ITIM) and activation motifs 
(ITAM), the function of these proteins have yet to be understood outside of B cell 
maturation and immune modulation. Recent research has revealed that FCLR6 binds 
HLA-DR (MHC Class II) molecules and is upregulated in late stage HIV (Kulemzin et al., 
2011, p. 6)(Schreeder et al., 2010). Moreover, FCRL5 has been shown to bind IgG by a 
mechanism different from FcγR, and FCRLA has proven ability to bind IgG, IgA and 
IgM (Wilson, Fuchs, & Colonna, 2012, p. 5)(Santiago et al., 2011).  
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Table 3. FcRL Receptor Family. Prior to the grouping of FcRL family, the receptors 
carried a number of different names based upon other characteristics and functions.  
 
Neonatal Fc Receptor  
The neonatal Fc receptor (FcRn) is best known for its function in the placenta 
where it passively transports IgG from mother to child for early immunity. The function 
of FcRn in adulthood is primarily the regulation of IgG and albumin levels in the serum 
and transport of IgG across polarized cells. It has also been found in hematopoietic cells 
where it regulates MHC class I and II presentation by dendritic cells to the cells of the 
adaptive immune system (Roopenian & Akilesh, 2007). Recently it was demonstrated 
that FcRn was responsible for bidirectional transport of IgG across polarized epithelial 
cells of the gastrointestinal tract in a pH dependent manner (Rath et al., 2013). Due to its 
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dual role in immune system activation and IgG transport, it has been the focus of research 
to elucidate its possible role in disease mechanisms and prevention. 
FcRn was first isolated in the rodent gut as a heterodimer made of a 50 kDa 
MHC-I-like heavy chain non-covalently bonded to a 12-kDa β2-microglobulin light chain 
(Rath et al., 2013). The receptors bind IgG in a 2:1 ratio in its CH2 and CH3 regions of 
the Fc domain. It has also been shown that IgG binding occurs ideally at a pH 5-6, while 
it does not occur at a neutral or basic pH (Rath et al., 2013).  
Although FcRn’s pH dependency has been clearly demonstrated in numerous cell 
types, experiments have revealed two different possible IgG binding mechanisms for the 
receptor. The most commonly accepted mechanism demonstrated in vitro is the 
endocytosis of fluid containing IgG into acidic endosomes in which the activated FcRn 
binds the IgG molecule, protects it from lysosomal degradation and then releases to 
antigen-presenting cells (APCs) when exposed to the basolateral, neutral intracellular 
milieu. The acidic environment of the endosome thus provides a way for FcRn to activate 
and bind IgG within the endosome while still being able to release the molecule when 
exposed to the neutral pH of the basolateral or apical surfaces.  
However, it is also possible that the acidic environment required for FcRn 
function is derived from phagocytosis of acidic luminal contents, and not necessarily the 
endosome. One study has shown that when placed in a reservoir of pH 6, IgG can be 
trancytosed readily across Madin-Darby canine kidney (MDCK) cells, however when the 
reservoir is buffered to pH 7.4, minimal IgG transport is seen (Claypool et al., 2004). 
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Moreover, the same results have been seen in experiments involving trancytosis of HIV-
coated IgG across HEC-1A monolayers (Gupta et al., 2013). If endosomal acidification 
was the mechanism in which FcRn functioned in vivo, the pH of the luminal contents 
should not make a difference in amount of IgG trancytosed. 
It is also not known whether its function in polarized epithelia aids or hinders 
viral transmission. In a recent study conducted utilizing Y8-10C2 influenza 
hemagglutinin-specific monoclonal antibody, it was shown that this antibody is able to 
function intracellularly in a FcRn-dependent fashion to reduce viral replication in MDCK 
cells after apical exposure to the influenza virus (Bai et al., 2011). This elucidated a 
possible protection mechanism utilizing the function of FcRn. However, it has also been 
shown that FcRn can transport infectious HIV in immune complexes across epithelial 
cells following addition of non-neutralizing monoclonal or polyclonal IgG antibodies to  
HIV (Gupta et al., 2013). 
Finally, there is a lack of characterization of the FcRn receptor in the female 
reproductive tract where its function could be relevant to sexual transmission of HIV. 
Although one study has explored its function and characterization in vaginal models, 
results of this study have yet to be reproduced and given biological relevance (Li et al., 
2011). This thesis serves to further elucidate the expression and function of this receptor 
not only in vaginal, but also endocervical models. 
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The Polymeric Immunoglobulin Receptor 
 The polymeric Ig receptor (pIgR), previously known as the membrane secretory 
component (SC), is a 100 kDa glycoprotein expressed on the basolateral surfaces of 
secretory epithelial cells where it binds J-chain-containing pIgA and pentameric IgM in a 
non-covalent fashion. Upon reaching the apical surface of epithelial cells, secretory IgA 
(sIgA) or IgM (sIgM) are exocytosed into the lumen, while the c-terminal segment of the 
receptor remains intracellular and is eventually degraded.  The receptor has shown high 
constitutive expression in secretory epithelial cells and is upregulated by IFN-γ 
(Brandtzaeg, 2013). Most importantly, sIgA has a number of proven anti-microbial 
effects including microbial agglutination, virus neutralization, non-inflammatory 
extracellular and intracellular immune exclusion via inhibition of epithelial adherence 
and cross-reactive protection (Brandtzaeg, 2013). Since local production of sIgA has 
been identified in the FRT, and most prominently in cervical secretions and vaginal 
secretions (Kutteh & Mestecky, 1994), pIgR was included in our study as another Ig 
transport protein. 
The Future of HIV Vaccinology: Broadly Neutralizing Monoclonal Antibodies 
 Normally viral vaccines are manufactured based on a particular antigen that can 
elicit an immune response which remains in the memory of the adaptive immune 
response. In HIV, finding that particular antigenic target has been challenging due to its 
immense mutability and diversity which allows molecules to quickly evade antibodies. 
For example, gp120 on the viral envelope includes variable loops, N-linked glycosylation 
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and conformational flexibility allowing it to hide the receptor-binding site from humoral 
defenses (Kwong, Mascola, & Nabel, 2012). Despite this, many broadly neutralizing 
antibodies (bNAbs) have been found in HIV positive individuals that can react with most 
HIV viral particles and effectively neutralize them. The particular bNAb utilized in this 
thesis is VRCO1. It was discovered via isolation of B cells from the sera of HIV positive 
individuals expressing these “elite neutralizers,” cloning them and comparing their 
efficiency via high throughput assays of HIV-1 neutralization (Walker et al., 2011). 
VRCO1 functions by binding the initial CD4 binding site on gp120 and has exhibited an 
ability to neutralize over 90% of HIV strains. Moreover, VRC01 when administered to 
macaques has shown protection against SHIV challenges in both the rectal and vaginal 
mucosa (Kwong et al., 2012). 
Production of Novel Plantibodies 
Although, many antibodies have been proven effective in neutralizing HIV-1, 
mass production of these antibodies has been limited by cost and manufacturing 
capabilities. Traditionally, they were made by immunizing mice against a particular 
antigen and then extracting hybridoma cells that have grown from the fusion of myeloma 
cells with spleen cells. The myeloma cells provide the immortal growth patterns of cancer 
cells while spleen lymphocytes provide the antibody gene. Hybridoma cells can be 
injected into the peritoneal cavity of mice, where they can grow into antibody-rich tumors 
called ascites. This method has faced several challenges which include individual 
variability in antibody titers, unethical treatment of animals due to pain caused by ascites 
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and the high cost of facility maintenance (National Research Council (US) Committee on 
Methods of Producing Monoclonal Antibodies, 1999) 
A novel solution to these issues was production of monoclonal antibodies in 
plants utilizing vectors. The particular method utilized to create the VRC01 bNAbs was 
growth in Nicotiana benthamiana by Mapp Biopharmaceuticals Inc. It has two major 
advantages for mass production of efficient mAbs: (1) cost effectiveness, and (2) high 
purity. 
It takes only 8 days to infect mature N.benthamiana plants with Agrobacterium 
containing viral replicons, obtain a high copy number of antibody specific RNA, and 
extract required mAbs from cells (Whaley, Hiatt, & Zeitlin, 2011). This method is 
scalable without a need to change growing conditions or infection procedures, which 
allows the possibility of mass production. Genes are also not incorporated into the plant 
genome, which prevents transformation or mutation into the species via pollen or seed 
transfer. Finally, production is placed in a controlled environment (an indoor greenhouse) 
and no replication-competent virus is made or used during the process. 
Normally N.benthamiana glycosylates its proteins with xylose and fucose, both of 
which are not found in humans and therefore can affect efficiency and immune reactions. 
However, this method has been able to develop transgenic strains of N.benthamiana that 
have RNAi knocked out fucosyl and xylosyl tranferases, therefore producing mAbs that 
are identical those found in humans (Whaley et al., 2011). 
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New Age Microbicides and Plantibodies 
The promise of mAbs and novel plantibody production may lead to a new generation 
of effective safe anti-HIV microbicides. The history of microbicide development has 
been infamous for promising preclinical approaches that have ultimately failed in clinical 
trials.  The first major attempt at microbicide development focused on surfactant 
spermicide formulations. However, N9 spermicide showed not only insufficient HIV 
prevention in phase III clinical trials, but also disturbed the vaginal epithelial barrier with 
continued use enhancing the possibility for infection (Garg et al., 2009). Later, 
polyanionic compounds were utilized because they prevented viral cell entry in vitro. 
However, these formulations also lacked potency in preventing HIV transmission in 
phase III trials, causing a lull in microbicide formulations for a few years (Garg et al., 
2009).  
Currently, drugs normally incorporated into antiretroviral therapy are also being 
reformulated for the use of topical microbicides. One prominent example is the 
reformulation of tenofovir, a commonly used oral nucleotide reverse transcriptase 
inhibitor, in topically applied vaginal microbicide gels. Although results are still 
preliminary a recent trial has shown that in comparison to a placebo gel, tenofovir gel 
reduced HIV acquisition by an estimated 39% overall, and by 54% in women with high 
gel adherence with no increase in adverse events as seen in previous microbicide 
trials(Karim et al., 2010). However, recent failures of similar regimes utilizing tenofovir 
and novel pre-exposure prophylaxis agent Truvada in the VOICE and FEMPrep trials 
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have revealed that further investigation is required to see if this approach works 
(Quiñones-Mateu & Vanham, 2012) 
With the advent of bNAbs, it is now possible to formulate a microbicide that is 
specific to HIV envelope antigens and functions in the natural environment of the 
mucosal immune system. Moreover, a combination microbicide containing the most 
efficient HIV mAbs has already been manufactured in N.benthamiana and is being tested 
in animals. It has been estimated that 10,000 kg of mAb would be needed annually if 10 
mg of this formulation is used twice a week by 10 million women (Whaley et al., 2011). 
With the new plantibody technology the price per dose would be less than one U.S. 
dollar, making it a practical solution for formulating a female-controlled, cost-efficient 
prevention method against HIV infection (Whaley et al., 2011). 
Vaginal and Endocervical Tissue Models 
Due to the production of topically applied contraception, microbicides and 
feminine care products, there has been a significant need for vaginal and endocervical 
mucosal models for pre-clinical testing. Contraceptive components such as Nonoxynol-9 
(N9) have been shown to increase permeability, inflammation and lactobacilli death in 
the vaginal mucosa (Ayehunie et al., 2006). These effects can have a significant impact 
on local HIV transmission via sexual intercourse and could be detected prior to clinical 
testing if adequate tissue models were constructed. 
MatTek Inc. has developed a human vaginal tissue model called VEC. The model 
was constructed from human ectocervical or posterior vaginal epithelia obtained from 
hysterectomies of healthy women with benign indications. Tissue was then grown in 
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sterile culture, stripped of connective tissue, trypsinized and stratified to create a 
monolayer representing the stratified squamous epithelium of the vaginal ectocervix. The 
full-thickness VEC model (VEC-FT) was also constructed to better polarize the tissue to 
in vivo conditions by growing normal ectocervical fibroblasts and seeding epithelial cells 
on top of the matrix (Ayehunie et al., 2006).  
More recently, our laboratory has been collaborating with MatTek to construct the 
VEN model from human endocervical explants. The culture method has been very 
similar to the construction of the VEC model, however, VEN-FT has not been fully 
characterized and is only available as a prototype.  
Hypothesis 
  Since the neonatal Fc receptor, FcRn, is only expressed in the basal layer of the 
vaginal stratified squamous epithelium, it does not mediate apical to basal transcytosis in 
this tissue. In the endocervical columnar epithelium, however, it does mediate apical to 
basal IgG transcytosis. 
Specific Aims 
1. To characterize Fc receptor and pIgR gene expression in VEN and VEC tissues  
2. To analyze the effects of inflammation and menstrual cycle hormones on gene 
expression in VEN and VEC tissues 
3. To identify localization of FcRn protein expression in both VEN and VEC tissues 
4. To explore the FcRn-mediated IgG trancytosis mechanism in VEN and VEC 
tissue models  
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MATERIALS AND METHODS 
VEC and VEN Tissue Culture  
 Affimetrix gene microarray experiments were conducted with five sets of MatTek 
Corporation EpivaginalTM (VEC) and endocervical (VEN) tissue models following 
hormone or immunostimulant treatment. The VEC tissue model (EpivaginalTM) is fully 
differentiated, stratified squamous epithelium that is derived from primary human 
vaginal-ectocervical epithelial cells and morphologically resembles normal vaginal tissue. 
Our lab has been involved in the process of constructing and troubleshooting both the 
VEC and VEN models with MatTek since its conception.  
The original VEC model was constructed by first obtaining ectocervical tissue 
from hysterectomies of healthy women between the ages of 34-44. The tissue was then 
processed within 24 hours by first incubating in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Cambrex, MD) with added penicillin, streptomycin, and gentamicin (10 mg/ml, 
Cambrex). After removing the connective tissue from the epithelial layer, it is cultured in 
DMEM with 10% fetal bovine serum (FBS) at 37°C and 5% CO2 in order to isolate 
fibroblast cells. The epithelial portion was incubated in  0.025% trypsin/0.025% EDTA 
(Cambrex), for 1 h at 37°C and 5% CO2 and gently stirred for an additional hour in order 
to extract individual cells. Further details regarding the specific culture and extraction of 
the cells can be referenced in Ayehunie et al. (2011). 
Tissue stratification of VEC-100 was achieved by plating thawed cryopreserved 
cells on to 50-mm petri dishes. After they had reached 60–70% confluence, cells were 
	   27	  
extracted and seeded onto polycarbonate tissue culture treated microporous membrane 
cell culture inserts (NalgeneNunc International, Naperville, IL). The tissue was then 
cultured at 37°C, 5% CO2, 98% rH for 4 days submerged in medium and 7 days at the air 
liquid interface using a serum free differentiation medium (VEC-100-MM, MatTek 
Corporation, Ashland, MA)(Ayehunie et al., 2011). The full-thickness Epivaginal model 
(VEC-FT) incorporates the fibroblast layer by culturing extracted fibroblasts in a 
collagen solution to form a fibroblast-collagen gel matrix. After the gel is formed, the 
VEC epithelial cells are seeded on top of the matrix and grown for 4 days submerged in 
medium and for 7 days at an air-liquid interface(Ayehunie et al., 2006) 
VEN tissue was constructed using a similar process, but utilizing donor 
endocervical tissue and a slightly different growth medium. Although partial thickness 
(VEN-PT) has been achieved for this model, full thickness VEN (VEN-FT) has yet to be 
successfully constructed. A table of hormones and immunostimulants incubated with the 
tissues, their respective concentrations and incubation times are included in Figure 7.   
Microarray 
VEC and VEN tissue were constructed, incubated under various hormonal and 
immunostimulant treatments and provided to us by MatTek Corporation. RNA was 
extracted from the tissues and the samples were provided to Boston University 
Microarray Core facility for processing using the Affymetrix GeneChip Gene 1.0 ST 
Array System. After QC via Bioanalyser and normalization, expression data was 
provided by the array core and analyzed further via DAVID (Database for Annotation, 
	   28	  
Visualization and Integrated Discovery) analysis to characterize upregulation or 
downregulation of gene expression pathways. 
First, genes with expression values below the median in all samples were 
removed from the raw data. Then all genes were ranked by absolute variance across all 
samples and the bottom 50% of values were removed to reduce the impact of technical 
variance between arrays. Finally, the remaining expression values were converted to log2 
expression units in order to normalize the data points. Gene expression values were then 
divided into three categories: not expressed (values that fall within the first tertile), 
marginally expressed (values that fall between the first tertile and median value), and 
significantly expressed (values above the median). 
Quantitative RT-PCR  
To further confirm microarray results, quantitative reverse transcriptase PCR (RT-
PCR) was performed for selected gene transcripts. RNA was extracted from VEC and 
VEN tissues after incubation with various treatments in their respective well inserts 
utilizing Qiagen RNeasy Plus Mini Kit (50x) (Qiagen, Valencia, California) according to 
the manufacturer’s protocol (RNeasy® Plus Mini Handbook (2010), Qiagen) or by 
Ambion RNAqueous® Total RNA Isolation Kit. The tissue lysis step was performed 
utilizing a handheld tissue ruptor and passing lysate through a 20-gauge sterilized syringe 
5 times. First-strand cDNA was synthesized from 1-2 ug of RNA with TaqMan reverse 
transcription kit (Applied Biosystems, Foster City, California).  
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Quantitative PCR was performed with 1uL and 0.5 uL cDNA with Applied 
Biosystems® TaqMan® Gene Expression Master Mix and specific primers. For FCGRT 
quantification, TaqMan® Gene Expression Assay primer Hs00175415_m1 was used with 
an amplicon size of 115 bp and spanning exon regions of 5-6 and 4-5. Applied 
Biosystems® Eukaryotic 18S rRNA Endogenous Control (FAM™ Dye⁄MGB Probe, 
Non-Primer Limited) was utilized as the endogenous control primer with an amplicon 
size of 187 bp.  
Amplification products were measured using ABI PRISM 7700 Sequence 
Detection System (Perkin-Elmer Applied Biosystems, Foster City, California) 
continuously during 40 cycles with a reaction amount of 20 uL. The relative amount of 
FcRn mRNA was calculated using the comparative cycle threshold (CT) method 
according to the ABI PRISM 7700 Sequence Detection System Chemistry Guide.  
Immunohistology 
Both VEC and VEN hormone-treated tissues along with endocervical and 
ectocervical tissue explants from healthy women at hysterectomy were stained for FcRn 
protein expression utilizing DAKO LSAB+ System-AP. Tissue samples were initially 
embedded in paraffin wax, and sectioned for individual staining. Slides were de-waxed 
with a 10-step process of submersion for 5 minutes each: Pro-Par (4x), 100% ethanol (3x), 
95% ethanol (1x), 70% ethanol (1x), distilled water wash (1x). Tissues were then placed 
in a decloaking chamber (DC2002) to reveal antigenic determinants, rinsed with distilled 
water and placed in 10 % Tris Buffered Saline (TBS) for 5 minutes.  After blocking the 
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tissues with donkey serum to prevent non-specific antibody binding for 20 minutes, a 
1:100 diluted primary anti-human FcRn antibody was added to the tissues and incubated 
for 2 hours. Only antibody diluent was added to negative control tissues. After washing 
with TBS 1x solution, the samples were incubated with LINK biotinylated antibody 
(DAKO) for 30 minutes.  The stain was developed by incubating with streptavidin-
alkaline phosphatase (DAKO) for 20 minutes and substrate chromagen solution for 10 
minutes (DAKO). Finally, the reaction was stopped with distilled water and 
counterstained with hematoxylin. 
IgG Trancytosis Assay 
 VEC-FT and VEN-PT were grown in 0.4 µm Millicell Hanging Cell Culture 
Inserts with polyethylene terephthalate membranes (Millipore). 50 uL of purified human 
serum from AB plasma male (Sigma-Aldrich) or VRC01 mAb with a concentration of 
5mg/mL IgG was added to the apical side of the wells. 10 uL of 5 ug/mL of sodium 
fluorescein salt (Sigma-Aldrich) was added to each well as a measure of membrane 
leakiness and integrity. The basal supernatant was collected at both 3 hour and 20 hour 
time points and was quantified with a 96-well IgG human ELISA kit (Abcam) according 
to the manufacturers protocol to measure the level of IgG trancytosis. Sodium fluorescein 
levels in the basal supernatant were measured separately at 460 nm as an indicator of 
tissue leakiness and membrane integrity. 
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RESULTS 
Specific Aims 1 and 2: Characterize expression of Fc receptors and pIgR in VEC 
and VEN, and explore possible influences of menstrual cycle hormones and 
immunostimulants 
 All microarray values are presented in log2  units to normalize the data and have 
been organized into three levels of significance. Genes with expression values that fall 
below 3.8 log2  units are considered to not be expressed; values that fall within 3.8-4.8 
log2  units are considered to have low expression and values above 4.8 are considered to 
be highly expressed.  Only genes that were expressed above 3.8 log2  units are included in 
the results, however many other Fc receptor genes were detected at levels below 3.8. 
Differences in gene expression levels were assigned significance of true change in 
expression if expression changes were greater than 2 fold and with a <0.05 p-value. 
Array Number Tissue Type Treatment Incubation 
Time 
1 VEC-PT 
VEC-FT 
• Growth medium only 
• Poly-IC  
• TNFα 
48 Hours 
2 VEC-PT 
VEC-FT 
• Growth medium only 
• Progesterone 
• Estrogen 
• Estrogen and Progesterone 
7 Days 
3 VEN-PT • Growth medium only 
• Estrogen 
• Estrogen and Progesterone 
7 Days 
4 VEC-PT • Growth medium only 
• Estrogen 
• Estrogen and Progesterone 
• DMPA 
7 Days 
Table 4. Table of Tissue Microarray Conditions. Each tissue that was treated with 
hormones received the following concentrations: 75nM estrogen, 700nM progesterone, 
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130nM DMPA, or 75nM estrogen plus 700nM progesterone. Immunostimulants were 
administered at the following concentrations: 10ug/mL TNFa and 25ug/mL Poly IC. 
Concentrations were derived from natural hormone levels during the secretory phase of 
the female menstrual cycle and average concentrations of immunostimulant required to 
induce inflammatory reactions in tissue. 
 
 
Receptor 
PT + 
M PT + Poly-IC PT + TNFα FT + M FT + Poly-IC 
FT + 
TNFα 
FCAR 3.49 3.91 4.00 3.49 3.40 3.79 
FCRL1 4.07 4.02 4.37 3.64 3.75 3.74 
FCGBP 4.51 4.27 4.63 3.73 3.71 4.02 
FCRLB 4.63 4.62 4.77 4.64 4.38 4.47 
FCGRT 5.66 5.75 5.87 5.65 5.30 5.55 
PIGR 5.83 5.70 6.05 3.34 3.47 3.45 
 Table 5.  Results of Array 1 VEC-PT and VEC-FT. VEC tissue was incubated with 
medium, Poly-IC or TNFα to detect changes in Fc receptor expression due to 
inflammation. Values highlighted in yellow indicate highly expressed genes. FCAR is the 
Fc fragment of IgA receptor gene and FCGBP is the Fc fragment of IgG binding protein 
gene. 
 
Array 1 revealed that a number of Fc receptors and Fc receptor-like genes were 
expressed in VEC-FT and PT incubated in medium only. Highest expression values were 
detected for FCGRT (FcRn) and PIGR (pIgR) genes, and significant expression of novel 
FCRL1 and FCRLB receptors was also found. Significant influence of poly-IC or TNFα 
treatment on expression of these genes was not found in VEC-FT or VEC-PT. The only 
variable that revealed a difference in gene expression was FT tissues verses PT tissues in 
expression of PIGR gene. This may be due to FT tissues being fully differentiated and 
therefore presenting decreased protein production, while PT tissues are less polarized and 
differentiated.  
	   33	  
 
 
Receptors FT-C PT-C FT-P PT-P FT-E PT-E FT-EP PT-EP 
FcεRIγ 3.91 4.09 4.03 3.88 4.01 4.07 4.04 4.07 
FcγRIIB(CD32) 4.05 4.03 4.19 4.43 4.33 4.31 4.26 3.78 
FCRL2 4.17 4.04 4.05 4.17 4.19 4.06 4.14 4.28 
FCRLA 4.71 4.52 4.81 4.59 4.62 4.50 4.83 4.43 
FCRL6 4.83 4.93 4.79 4.82 4.73 5.15 4.79 4.79 
FCAR 5.21 5.51 5.30 5.37 5.24 5.52 5.29 5.33 
FCRL1 5.53 5.56 5.37 5.55 5.53 5.68 5.41 5.48 
FCRL3 5.58 5.76 5.15 5.77 5.51 5.77 5.36 5.58 
FCAMR 5.61 5.51 5.41 5.43 5.36 5.71 5.53 5.56 
FCGBP 5.74 5.95 5.63 5.79 5.69 6.15 5.86 5.85 
FCRLB 6.11 6.24 6.16 6.15 6.11 6.03 6.31 6.13 
PIGR 6.87 8.04 7.16 8.03 6.56 7.09 6.65 7.36 
FCGRT 7.63 7.68 7.71 7.58 7.71 8.00 7.59 7.88 
Table 6.  Results of Array 2 VEC-PT and VEC-FT. Tissues were treated with medium 
(C), Progesterone (P), Estrogen (E), or Estrogen and Progesterone (EP) for 7 days. 
Values highlighted in yellow indicate highly expressed genes 
 
Array 2 confirmed the expression of PIGR, FCGRT and several FC receptor-like 
genes in VEC tissue. Over two-fold difference in PIGR gene expression was also 
detected between FT-C (Control) and PT-C (Control) with higher expression in the VEC-
PT tissue. Effects of hormone treatment on gene expression all fell below the two-fold 
change required for significance. An almost two fold decrease in expression of FCGRT 
was seen in VEC-PT E when compared VEC-PT C or VEC-PT P, although the difference 
fell below the significance threshold. 
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Receptor Untreated  Estrogen E2 + P 
FcεRII (CD23) 3.88 3.89 3.88 
FCRL1 4.28 4.26 4.21 
FCRL6 4.34 4.42 4.29 
FCAR 4.30 4.37 4.20 
Human Fc Gamma BP 4.46 4.52 4.51 
FCAMR 4.46 4.52 4.51 
FCRLB 5.73 5.66 5.71 
FCGRT 5.87 6.03 5.88 
PIGR 9.75 9.40 9.77 
Table 7.  Results of Array 3 VEN-PT. VEN tissue was treated with medium (untreated), 
E or EP for 7 days. Values highlighted in yellow are highly expressed genes 
 
 Array 3 showed the highest expression of PIGR in VEN tissue across treatments, 
in addition to high expression of both FCGRT and FCRLB genes. High expression of 
PIGR could be due to the important role of PIGR in maintaining IgA in cervicovaginal 
secretions. Moreover, both FCGRT and FCRLB function intracellularly and therefore, 
could have commonality in their regulation pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.  Results of Array 4 VEC-PT. VEC tissue was treated with medium (untreated), 
E, EP or DMPA for 7 days. Values highlighted in yellow mark highly expressed genes 
 
Array 4 confirmed high expression of FCGRT, PIGR, FCRLB and FCRL1 in 
VEC tissues. It also detected high FCGBP expression, which is important in producing 
Receptor Untreated  Estrogen E2 + P DMPA 
FcεRII (CD23) 4.02 4.00 3.92 3.98 
FCAR 4.38 4.17 4.15 4.14 
FCAMR 4.53 4.47 4.27 4.30 
FCRL6 4.61 4.41 4.35 4.41 
FCRL1 5.00 4.80 4.83 4.85 
FCGBP 5.06 5.18 5.00 5.02 
FCRLB 5.84 5.61 5.57 5.61 
PIGR 5.81 5.27 5.20 6.61 
FCGRT 6.87 6.66 6.54 6.49 
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FC binding proteins. The most interesting change in gene expression was found in the 
effect of DMPA treated tissues, which showed an over two fold higher expression of 
PIGR than tissues treated with E or E and P. This effect is unusual because pIgR protein 
is not found in large amounts in the vaginal epithelium, although the gene itself may be 
expressed.  Polymeric IgA transport in the FRT occurs primarily in the endocervix and 
uterus, and therefore the influence on gene expression in the vagina is particularly 
interesting. 
 
Relative Quantification of FCGRT by RT-PCR  
Preliminary quantitative RT-PCR experiments were conducted to validate the results 
found in the microarray. Only arrays that displayed greater than two fold changes in gene 
expression were selected for relative quantification assay due to limited RNA sample. 
This included Array 2, 3, and 4 which showed changes in PIGR expression. RQ values 
were calculated according to ABI PRISM 7700 Sequence Detection System Chemistry 
Guide. 
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Figure 4.  Relative Expression of PIGR in Array 4 VEN-PT, assessed by 
quantitative RT-PCR. Results of amplification with cDNA made from VEC tissue 
treated with medium (untreated), E, EP or DMPA for 7 days.  
 
 Since several of the arrays revealed an over two fold change in PIGR expression 
under DMPA treatment and between FT and PT tissues, RT-PCR was used to further 
confirm this change in expression. However, in our pilot experiments, these gene 
expression changes in PIGR were not clear amongst the replicates. A histogram from 
Array 4 RT-PCR experiments was included above as a representation of type of variation 
found between replicates. This data should have shown a clear increase in PIGR 
expression in DMPA treated tissue, however only one replicate of DMPA treated tissue 
showed a clear difference in expression levels from the untreated samples, while others 
did not. Thus, it is difficult to make any conclusion regarding hormonal effects from this 
data, and further investigation of both the sample and the primer must be performed to 
better understand the source of variation.  
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The variance could be due to inherent differences between replicate tissues in VEN 
and VEC models or other technical issues. Pilot experiments utilizing a custom designed 
primer in a nested RT-PCR reactions are now being conducted in an attempt to more 
clearly elucidate quantification and confirm microarray findings.  
Specific Aim 2: To localize FcRn protein expression in VEN and VEC tissue models 
and in vaginal and endocervical explants 
 
 
Figure 5. Expression of FcRn in VEN-PT and Endocervical Explant C58. 
Immunohistological staining of FcRn (red) in (A) VEN-PT tissue, (B) explant control 
tissue, (C) and (D) endocervical tissue explants C58. In VEN-PT staining is spread 
throughout the basal cells, while endocervical explants show varied expression both 
localized to the base of columnar epithelial cells as well as spread throughout. Photo 
courtesy of Jeffrey Pudney. 
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FcRn protein is visible throughout the basal columnar cells in the VEN-PT model 
without clear localization within the cells. In the endocervical tissue explants, different 
sections from the same donor reveal that FcRn can be expressed localized to the basal 
portion of the columnar cells, but can also be found spread within different areas of the 
columnar cells. An important difference to note when comparing endocervical explants to 
the VEN-PT monolayer is that the VEN tissue does not have a well-defined columnar 
epithelium. Due to the growth of multiple cell layers on top of the basal columnar layer 
polarization could be disrupted and therefore affect normal localization of protein.  
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Figure 6. Expression of FcRn in Ectocervical Explant C58 and VEC-PT Control, 
Estrogen and Progesterone Treated Tissues.  Immunohistological staining of FcRn 
(red) in (A) VEC-PT estrogen treated tissue, (B) VEC-PT control tissue (no antibody 
added), (C) VEC-PT progesterone treated tissue, and (D) ectocervical tissue explant C58. 
Photo courtesy of Jeffrey Pudney. 
 
Estrogen treated VEC tissue showed clear expression of FcRn protein localized to 
basal epithelial cells of the stratified squamous VEC-PT. Moreover, progesterone treated 
tissue, and ectocervical explant showed little staining for FcRn showing a possible effect 
of progesterone treatment on protein expression that was not seen in gene expression of 
FCGRT in microarrays. Ectocervical explant staining also confirmed little staining of 
!" #"
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FcRn protein in normal vaginal tissue. Both VEC tissue models and ectocervical explants 
displayed clear localization of FcRn to the basal portion of the epithelium.  
 
Specific Aim 3: To confirm FcRn-mediated IgG trancytosis mechanism in VEN and 
VEC tissue models 
50 uL of purified human serum from AB plasma male (Sigma-Aldrich) or VRC01 
mAb with a concentration of 5mg/mL IgG was added to the apical side VEC-FT and 
VEN-PT were monolayers on well inserts. After 3 hours, tissue was preserved and 
stained for IgG penetrance.  
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Figure 7. Penetration of VRCO1 into VEC-FT Tissue at pH 6 and 37°C  
Fluorescence staining of: (A) VEC-FT control tissue (no antibody), and  (B) VEC-FT 
tissue incubated for 3 hours with VRCO1 added to the apical surface. Photo courtesy of 
Jeffrey Pudney 
 
 VRCO1 did not penetrate visibly past the stratum corneum (apical) layer of the 
VEC-FT tissue and does not show clear trancytosis within cells	  at	  pH 6 and 37°C.  
Acidic pH and warm temperatures should be conducive to IgG transcytosis via FcRn, 
however this staining supported ELISA findings that little IgG was able to transcytose to 
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basal supernatant even under ideal conditions. This could be due to the significant 
thickness of the VEC-FT epithelial layer and the localization of FcRn to the basal cell 
layer. 
 
 
Figure 8. Penetration of Human Serum IgG and VRCO1 into VEN-PT Tissue at pH 
6 and 37°C Fluorescence staining of IgG in (A) VEN-PT control tissue (No IgG added),  
(B) VEN-PT tissue incubated for 3 hours with human serum IgG applied to the apical 
surface, and (C) VEN-PT incubated for 3 hours with VRCO1 added to the apical surface. 
Photo courtesy of Jeffrey Pudney. 
 
No IgG or VRCO1 penetrated past the apical surface of the epithelial layer of the 
VEN model under acidic conditions and warm temperatures, which are conducive to the 
FcRn mechanism. Similar results were seen with both VRCO1 and human serum IgG at 
!" #"
$"
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pH 7 and 4°C.  It is possible that transcytosis did not occur because the VEN model is not 
a true polarized columnar epithelium. The cells sitting above the basal epithelial cell are 
an artifact of the model construction and did not visibly express FcRn protein, and 
therefore may have prevented the FcRn-mediated IgG trancytosis mechanism of the 
columnar cells beneath them. 
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Figure 9. Penetration of VRCO1 into VEC-FT and VEN-PT Tissue at pH 7 and 
37°C.  High magnification of fluorescence staining of: (A) VEC-FT tissue and (B) VEN-
PT tissue, both incubated for 3 hours with VRCOI added to the apical surface. Photo 
courtesy of Jeffrey Pudney 
 
Under neutral pH conditions and warmer temperatures, VRCO1 once again did 
not show significant penetrance past the stratum corneum layer of VEC-FT or the apical 
surface of VEN-PT. However, what was more interesting was that a closer look at the 
fluorescence staining (A) reveals VRCO1 penetration in between epithelial cells. With a 
!"
#"
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closer examination of the VEN-PT model (B), the unique behavior of VRCO1 
penetration between cells was seen again. Moreover, the inaccurate cell morphology is 
also more delineated as the cells are visibly stratified and squamous in character when the 
true endocervix is a singular layer of tall, columnar cells. Since this was not seen with 
human serum IgG incubation, it is possible VRC01 differs in transport or is better suited 
to penetrate around loose cells on the apical surface layers of the stratified VEC-FT 
epithelium. 
 
Figure 10. IgG Concentration in Basal Supernatant of VEC-FT and VEN-PT at 3 
Hours.  IgG transport across VEC and VEN tissue was assessed after 3 hours. Duplicate 
samples (1 and 2) were run at pH 6 or 7 and at 37°C or 4°C.  Unlabeled samples in the 
graph were conducted in VEN-PT tissue. N represents negative wells with only media, 
NHS represents normal human serum and VRC01 is a mAb against HIV. 
Our pilot experiment to determine IgG levels in VEC and VEN tissue basal 
supernatants by ELISA revealed some inconsistent data.  The majority of wells had levels 
of IgG below the lowest detection threshold of the kit which was 15 ng/mL. Thus, it can 
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be considered that wells with IgG concentrations that fell below zero did not have any 
IgG apical to basal transcytosis.   VRC01-1 in VEN-PT under acidic pH showed high IgG 
concentration in its basal supernatant compared to other samples. When sodium 
fluorescein concentration was measured, all tissues showed very little passing of 
fluorescein into the basal supernatant. Therefore, the high concentration of IgG cannot be 
attributed to a generalized leakiness of the tissue membrane. Interestingly, serum IgG did 
not cross the VEN epithelium under any of the conditions.  This could be due to a 
difference in structure of the two molecules and its influence on the FcRn mechanism.  
As described earlier, Li et al. (2011) reported that FcRn mediated IgG transcytosis 
across VEC-FT epithelial cells in an acidic environment.  We could not confirm this 
result.  No IgG (from serum or VRCO1) was observed in the basal wells of any of the 
VEC cultures. Unlike in the VEN cultures, in the VEC-FT tissue no difference was 
detected in transcytosis of VRC01 between samples incubated at pH 6 and pH 7. This 
phenomenon can be explained by the difference in morphology between VEC-FT tissue 
and VEN-PT tissue. VEN tissue not only is thinner and comprised of columnar cells, but 
also does not contain the additional fibroblast-derived layer, which could significantly 
prevent IgG from reaching the basal supernatant. Moreover, our immunohistology 
experiments revealed expression of FcRn protein only in the basal layer of VEC tissue; 
therefore it may have not have been able to access IgG applied to the apical surface of the 
tissue. 	  
	   47	  
 
Figure 11. IgG Concentration in Basal Supernatant of VEC-FT and VEN-PT at 20 
Hours.  IgG transport across VEC and VEN tissue was assessed after 20 hours. Duplicate 
samples (1 and 2) were run at pH 6 or 7 and at 37°C or 4°C.  Unlabeled samples in the 
graph were conducted in VEN-PT tissue. N represents negative wells with only media, 
NHS represents normal human serum and VRC01 is a mAb against HIV. 
The major difference between the IgG concentrations in supernatants collected at 
3 hours and 20 hours was in the pH 7 incubated tissues. Both of the VRC01 VEN-PT and 
the VRCO1 VEC-FT tissues at pH 7 showed increased levels of IgG in basal supernatants, 
whereas only one VRCOI VEN-PT well showed transcytosis at pH 6. Moreover, no 
transcytosis of IgG from human serum was observed at either pH 6 or 7. Since this was a 
pilot experiment, future experimentation is necessary to elucidate the FcRn-mediated IgG 
transcytosis mechanism in these tissues. 
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DISCUSSION 	   The aim of this thesis was to characterize the expression of Fc receptors and pIgR 
in vaginal and endocervical epithelia, explore the possible effects of menstrual hormones 
and inflammation on expression, and finally to explore the FcRn-mediated IgG 
transcytosis mechanism in VEN and VEC tissue models.  
Microarray analysis indicated high expression of both FCGRT and PIGR genes 
for FcRn and pIgR respectively, with higher expression in VEN (endocervical) tissue vs. 
in VEC (vaginal) tissue. This observation confirms literature that has described higher 
pIgR expression in the cervix in comparison to the vagina and is further supported by 
findings of greater protein expression in the polarized columnar epithelium of the 
endocervix (Kutteh & Mestecky, 1994)(Fichorova & Anderson, 1999). This is the first 
time FcRn expression has been described in endocervical tissue. DMPA treatments and 
polarization produced greater than 2 fold changes in pIgR expression in VEC tissues. 
Hormonal effects on FCGRT expression were not detected by microarray. Surprisingly, 
immunostimulant treatments (TNFα or Poly I:C incubation) did not affect  expression 
levels of either PIGR or FCGRT. As mentioned previously, IFN-γ treatment has shown 
upregulation of pIgR in secretory epithelial cells (Brandtzaeg, 2013).  
Immunohistological staining localized the expression of FcRn protein towards the 
base of the columnar epithelial cells of VEN-PT, and found FcRn to be expressed 
throughout the cells in endocervical explant tissue. A visibly greater amount of FcRn 
staining in the VEN tissue as compared to the VEC models was also observed. 
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Due to the high variability amongst replicates in pilot quantitative RT-PCR experiments, 
hormonal influence on FCGRT gene expression was not confirmed. Therefore, the lack 
of hormonal effect will have to be further studied when the model has been better 
constructed to represent the true endocervix and can be uniform from well to well.   
In microarray experiments with VEC-PT and FT tissue, FCGRT and PIGR genes 
were found to be highly expressed and not influenced by menstrual cycle hormones or 
immunostimulants. Epithelial polarization was observed as the most significant variable 
in accounting for a greater than 2 fold decrease in PIGR expression since VEC-PT 
displayed an increase of expression in comparison to VEC-FT. Moreover, in array 4 
DMPA treated tissue had an over two fold higher expression of PIGR than both E treated 
samples and E and P treated samples in that microarray. This effect was not confirmed by 
RT-PCR data due to high variability amongst replicates, but is an effect that is worth 
investigating in the future. Immunohistological staining showed localization of FcRn to 
the basal epithelial cells of the vagina and stained less prominent than in VEN tissue. 
Moreover, progesterone and untreated tissue stained fewer FcRn protein granules than 
VEC-PT estrogen treated tissue. This finding contradicts current literature on the 
localization of FcRn in vaginal epithelium that observed the protein to be stained 
unlocalized, throughout the stratified vaginal epithelium (Li et al., 2011). 
Novel Fc receptor-like proteins were also found to be expressed highly in both 
tissue models. In VEN tissue, the gene for intracellular protein FCRLB was found to be 
expressed at the same high levels as PIGR and FCGRT. In VEC tissue a number of Fc 
receptor-like molecules were expressed including FCRL1, FCRL3, FCRL6, FCRLA and 
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FCRLB. No hormonal or immunostimulant effects were observed on Fc receptor-like 
gene expression. Although, the functions for these receptors have not been elucidated, 
high expression in both VEC and VEN tissues warrant further investigation.  
The FcRn-mediated IgG trancytosis mechanism reported by Li et al. (2011) in 
VEC tissue was not confirmed by ELISA or fluorescent staining results. The known 
mechanism as highlighted in literature regarding the intestinal epithelium requires 
activation in an acidic pH and does not occur at 4°C. However, the results of our 
preliminary experiment were inconclusive. The experiment revealed a possible difference 
in penetration characteristics of VRCO1 compared with human serum derived IgG. 
Further functional assays must be performed to understand whether or not this is a true 
result. Whereas VRCO1 crossed the epithelial layer in VEC tissue, we were unable to 
confirm FcRn-mediated transport since the antibody crossed over at pH 6 and 7 and at 37 
and 4 C.  The VEN-PT model showed stratified, squamous morphology, which is an 
inaccurate representation of the endocervix and could be the reason for inconsistent IgG 
trancytosis and penetrance into the basal supernatant. Moreover, it is possible that FcRn 
does not necessarily require an acidic environment in the lumen to become activated as it 
does in the intestine, but instead is able to acidify in the vesicle after capturing IgG from 
the surface. This would mean pH of the vaginal and endocervical lumen may not play as 
significant of a role as it may in other tissues where FcRn is utilized. More studies are 
needed to decipher whether IgG is transported by FcRn in vaginal and endocervical tissue 
models. 
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Expression of FcRn, Fc receptor-like proteins and pIgR in both endocervical and 
vaginal epithelial cells elucidate possibly novel pathways of monoclonal antibody 
transport and HIV transmission in the FRT. High FcRn expression particularly 
throughout columnar endocervical cells elucidates a possible bidirectional mechanism of 
HIV-IgG complex or mAb transcytosis across the endocervix, a site shown to be highly 
susceptible to HIV infection. Moreover, these findings have significant implications on 
testing of mAb formulations for HIV microbicides as it highlighted that VRCO1, a bNab, 
remains on the epithelial cells of both VEC and VEN models and does not penetrate 
deeper into the tissue. Although, further experimentation must be done to elucidate how 
exactly FcRn functions in VEC and VEN models and how effective it is in transporting 
antibodies complexed with HIV, its characterization in the models is a significant step in 
understanding its role in the FRT.  
CONCLUSION 
FcRn, alongside PIGR and novel FCRL receptors, were found to be highly 
expressed in both VEC and VEN tissue models. Effects of menstrual cycle hormones on 
gene expression were not detected in the tissues, however DMPA displayed a possible 
effect on PIGR expression in VEC-PT. Unlike previous characterization of FcRn in 
human vaginal tissue, protein expression seems to be localized to the basal portion of 
both VEC and VEN epithelial cells. The mechanism of FcRn-mediated IgG transport was 
not confirmed by either the VEC or VEN models, and may require further testing or a 
reexamination of the assumed conditions required for receptor function. With this 
information, further investigation of FcRn protein function in both the vaginal and 
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endocervical epithelia can be conducted and possibly elucidate novel viral entry or 
blocking targets in HIV transmission. 
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